Clinic Roundup

 Rexahn Pharmaceuticals Inc., of Rockville, Md., received approval from the Hungarian Regulatory Authority and Ethics Committee for its initial clinical trial application to begin a Phase I trial of RX-3117. Preclinical studies showed anticancer activity. The company plans to explore its potential in a broad range of cancers including colon, lung and pancreatic.